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Alzheimer’s disease (AD) is one of the most common types of degenerative 
dementia. Investigation into the mechanism of aggregation of the most potential 
Alzheimer’s protein, amyloid-beta (Aβ40) peptide suggested that the initial α-helical Aβ 
monomer structured transformed into an intermediate state of aggregation. Erythrosine B 
(ER) is a component of FDA-approved red food dye. Dr. Kwon at University of Virginia 
observed that the halogenated structure of ER inhibited the formation of Aβ fibril via in 
vitro experiments. Our group used computational molecular modeling such as AutoDock 
docking and molecular dynamics simulations to test the effect of ER and its modified 
version, EOY, on Aβ40 monomer. The drug candidates were modeled using Cerius2, and 
initial Aβ40 structure was obtained from the protein data bank (ID: 1BA4). AutoDock was 
used to perform molecular docking, and then molecular dynamics (MD) simulations were 
conducted using GROMACS 4.6.1 software package. An approximate binding site for 
each system was found using AutoDock. When the MD simulations were run, the drug 
molecules were located in the binding sites. Four analysis methods were used to 
investigate the interactions between Aβ40 and the drug candidates: comparison of the 
protein structures, secondary structure analysis, root mean square deviation (RMSD) of 
the protein’s position, and distance calculation between Aβ40 and the drug candidates. 
According to our analyses, ER was effective in preventing the conformational change of 








 Various human diseases, including some neurodegenerative diseases, have been 
found to be correlated to conformational transition of specific proteins from their natural 
forms into insoluble fibrillar forms [1]. Among those diseases, Alzheimer’s disease (AD) 
is known to be the most rampant, age-related dementia [1]. The exact pathological 
information of AD is still unclear, but many studies have shown that amyloid beta (Aβ), a 
type of neurotoxic protein, plays a crucial role in pathogenesis of AD. The natural Aβ 
peptides, which have helical structures, are not harmful; however, once they start to 
unfold, aggregate, and form fibrils or β-sheet structures, their neurotoxicity increases 
significantly. Due to this characteristic of Aβ, many researchers have attempted to 
discover or develop chemical compounds that can prevent the change in conformation 
through different approaches. 
Halogenation 
 Halogenation, a reaction that results from addition of the halogen to a compound, 
was found to be effective in terms of preventing fibrillogenesis or β-sheet structure 
formation [2]. Wong, Irwin, and Kwon applied the finding to test the effectiveness of 
erythrosine B (ERB), a content of red food dye, and its analogues, eosin Y (EOY), 
phloxine B (PHB), rose Bengal (ROB), and fluorescein (FLN) (negative control) on the 
Aβ conformational change via in vivo and in vitro methods [2]. However, no 
computational study has been conducted to validate the experimental results. Our 
research group decided to confirm the abilities of ERB (ER) and EOY, which were 
chosen to be the most effective chemicals by Wong, Irwin, and Kwon, through 
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computational molecular dynamics (MD) simulations. We used GROMACS software 
package and applied AMBER force field for the MD simulations. 
 Most of the studies in this field have been heavily focused on in vivo and in vitro 
tests. For our research group, which specializes in computational methods, those 
candidates and their modifications could be promising subjects. This research will 
contribute to improvement of the contents of Alzheimer’s drug in terms of accessibility, 
efficiency, and ultimately efficacy. 
Literature Review 
Alzheimer’s disease (AD) is one of the most common type of age-related 
dementia [3] that shows symptoms such as memory loss, declined cognitive skills, and 
sudden change in personality. Despite the amount of research being done, the exact 
pathological factor is still unclear. Several potential causes have been reported to be 
correlated to AD. One of the most popular beliefs is that amyloid beta (Aβ), a type of 
neurotoxic protein, plays a crucial role in pathogenesis of AD. According to previous 
studies, natural Aβ peptides which have helical structures are not harmful; however, once 
they start to unfold, aggregate, and form fibrils or β-sheet structures, their neurotoxicity 
increases significantly. Due to this characteristic of Aβ, many researchers have attempted 
to discover or develop chemical compounds that can prevent the conformational change 
through different approaches. However, because of some uncertainties of its structure and 
chemical properties, at this moment, it is not even easy to accurately and 
comprehensively define what Aβ is [3]. Thus, research is actively ongoing for a better 
understanding of the AD pathology and developing its novel treatment. 
Much effort has been made to understand the functioning of Aβ as a potentially 
major cause of AD and investigate its interaction with various drug candidates. Despite 
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some uncertainties about Aβ, it has been clear that its formation and aggregation increase 
neurotoxicity [3], so many studies were conducted to tackle the protein via different 
approaches. Aquizzi and O’Connor state that mainly three approaches or goals have been 
taken by researchers—inhibition of enzymatic activities that form Aβ from its precursor, 
enhancement of immune system to remove Aβ, and prevention of Aβ aggregation [3]. 
Even though many researchers have the same goal among the three popular ones, 
they still use different candidate compounds that have unique characteristics that they 
want to test. For instance, halogenation, a reaction that results in addition of the halogen 
to a compound, was found to be effective in terms of preventing fibrillogenesis or β-sheet 
structure formation [4]. Wong, Irwin, and Kwon applied the finding to conduct their 
research which was to test the effectiveness of erythrosine B (ERB), which contains four 
iodines and four carbon rings, and its analogues, EOY, PHB, ROB, and FLN on the Aβ 
conformational change via in vivo and in vitro methods [2]. They utilized Thioflavin T 
fluorescence assay, transmission electron microscopy (TEM), MTT reduction assay and 
others to test the compounds. ERB and EOY were found to be the most effective 
compounds [2], but the result has not been further validated in dry-lab environment. Thus, 
that gap was attractive to our computational research group. Our group is conducting 
research to investigate the mechanism of interactions between the drug candidates (ERB, 
EOY and others) and Aβ monomer via computer simulations using GROMACS and 
AMBER force field. 
 Many more studies have been conducted to understand how a compound can be 
considered effective in terms of preventing Aβ conformational transition. Li et al. tested 
their compounds, LRL22, LRL27, K162, and K182, but, uniquely, through computational 
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means [1]. They examined the compounds to observe their effects on Aβ monomer and 
oligomer conformational change and their relative effectiveness [1]. They concluded that 
influential candidates tend to interact with the hydrophobic core I region (residue 17-21) 
of Aβ monomer which is a favorable result regarding previous studies that discovered 
those residues’ role in promoting Aβ aggregation [1]. In addition, to being an efficient 
candidate, it should have high binding energy and/or high specificity for the area of 
interaction (i.e. it must be specific to hydrophobic core I, II or III region) [1]. The drug 
candidates, however, were only effective for Aβ monomer, but not oligomer [1]. Thus, to 
some extent, they contributed to establishing criteria for being efficient drug candidates. 
 Recently, Du et al. proposed another novel way to determine efficiency of drug 
candidates. They concluded that a drug candidate that can perform “dual function” can be 
regarded efficient [5]. Brazilin, their test compound, was found to be able to 
simultaneously perform two functions -- inhibitory and remodeling functions. In other 
words, brazilin does not only inhibit Aβ conformational change from helical to fibrillar 
structure, but also destabilize already-mature fibrils to turn into unorganized, less toxic 
substances [5]. Their finding can be appreciated because it shed light on improving 
current AD treatments’ efficiency and therapeutic capability by having one drug 
attacking in two different ways. 
 Despite the fact that most AD research targets Aβ protein, some of the studies 
investigate other types of proteins as potentially significant causes of AD. For instance, 
sets of studies were conducted to test drug candidates’ effect on cyclooxygenase (COX) 
[6]. COX level in the microglia and the hippocampus was discovered to increase in AD 
patients, thus promoting inflammation within the brain [6]. Irannejad et al. validated the 
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effect of new compound, 1,2-Diaryl-2-hydroxyiminoethanones and its modifications, but 
the more attractive and important feature about this experiment is to test the compounds’ 
effect on two targets, Aβ and COX. The paper concludes that the compound with 
methoxyl for its functional group (R) was the most effective in inhibiting the roles of Aβ 
and COX [6].  
 In conclusion, the attempt to unveil the mysteries about AD pathogenesis and 
function of its correlated proteins like Aβ and to investigate the mechanism of protein-
drug interaction has been ceaseless. Many of the experiments have been focused on 
biochemical means to study AD and drug candidates, but relatively fewer studies were 
done using computational methods. More computer-based molecular dynamics 
simulations should help researchers overcome some restrictions of wet experiment and 
provide deeper insight into the mechanisms on molecular level. Another important 
research gap that needs to be filled is the structure of Aβ oligomer. Its oligomer is more 
toxic and problematic than monomer, but yet there is no defined structure for the 
oligomer for use in computer simulations. Moreover, as shown in Irannejad et al.’s 
research, there may be more unrevealed factors that are correlated to AD pathology [6]. 
In spite of the need for more research, analyses of results still need to be thorough and 
flawless. The current study aims to contribute to the field of AD research by, first, 
verifying the result of Wong, Irwin, and Kwon’s study about halogenation [2] through 
computational means. This will guide some of the AD researchers to investigate other 
kinds of halogenated compounds. Potentially, some aspects from halogenation and 
mechanism of brazilin that allows its dual function can be merged for a stronger and 
more efficient compound. In the future, we will examine factors that might influence the 
abilities of the compounds such as their concentrations, pH of the environment, 
modification of Aβ and others. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
 The main goal of this study is to investigate how the two drug candidates, ER and 
EOY, are able to physically bind to single Aβ40 protein and prevent the deformation of 
the protein, the precondition of the Aβ40 aggregation. Furthermore, the effects of ER and 
EOY were compared to investigate the effect of halogen functional group on structural 
deformation of Aβ40. As a negative control, we also carried out simulations on Aβ40 
without any treatment. Initially, structures of the protein and the drugs were prepared, and 
the potential binding sites of the drugs on the protein were determined with docking 









 Molecular structure of Aβ40 monomer was obtained from protein databank 
(rscb.org. PDB ID: 1BA4) [7]. The structure was extracted from NMR experiments, 
which maintained its helicity in aqueous micellar environment. Chemical structures of 
ER and EOY were drawn using Cerius2 software [8], and energy was minimized using 
steepest descent gradient method to obtain reasonable structure. Then the partial charges 
of the drug molecules were calculated via ab initio calculations using Jaguar [9] to 
Figure 1. Chemical Structures of ER and EOY 
doi:10.1371/journal.pone.0057288.g001 [2] 
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describe non-bonded electrostatic interactions. Partial atomic charges of entire atoms 
were estimated to generate total molecular charges of -2 for both ER and EOY. 
LACV3P** basis set was used, and spin multiplicity for both compounds was set to 1. 
Among the calculation options, Mulliken population was chosen to characterize charge 
distribution throughout each molecule. 
Molecular Docking 
 Molecular docking between the protein and drug was investigated using 
AutoDock 1.5.6 docking simulation program [10]. To investigate the energetically stable 
binding sites for the drugs to Aβ40, the interaction energy grid was calculated surrounding 
the protein. Based on center coordinates and dimensions of the energy grid boxes, we 
performed docking simulations using AutoDock Vina to find the potential binding sites 
on Aβ40 protein for ER and EOY separately. Nine conformations with the lowest binding 
energy were calculated for each drug molecule, and the position with the lowest energy 
was chosen to the most stable binding site. Figure 2 shows the bindings sites for ER-Aβ40 
and EOY-Aβ40 with the estimated binding energy of -1.184 kJ/mol and -1.191 kJ/mol, 
respectively. After choosing the best binding site for each drug candidate, we made two 
systems by locating a 
molecule of ER and 
EOY near Aβ40 at the 





Figure 2. Most potential binding sites of ER and EOY on 
Aβ40 These were results of Autodock docking simulations. 
(Left) ER-Aβ40. (Right) EOY-Aβ40. 
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   Molecular Dynamics Simulations 
 GROMACS 4.6.6 software was used to perform molecular dynamics (MD) 
simulations. Three systems were examined in this study: Aβ40 with ER, Aβ40 with EOY, 
and Aβ40 by itself as a negative control. For all the GROMACS simulations, 
AMBER99SB-ILDN [11] force field was used to accurately describe secondary 
structures of the protein. To describe ER and EOY, we used DREIDING force field with 
the estimated electrostatic charges using ab initio calculations as discussed before [12]. 
Each system was put into the triclinic box whose size was set as shown in Table 1. Then 
each system was filled with water molecules which were described by simple-point 
charge (SPC) model [13]. To neutralize the system, 150 mM NaCl was added to the 
systems. 
 x (nm) y (nm) z (nm) 
Aβ40 Only 5.67025 3.68988 3.500 
Aβ40-ER 5.715 3.719 3.620 
Aβ40-EOY 7.000 7.000 7.000 
 
 There were four steps to MD simulations, first of which was to minimize the 
systems’ energies in order to make sure the systems were free of steric clashes. Energy 
minimization was performed applying steepest descent integration method for 50,000 
steps. After that, the systems underwent NVT equilibration for 800 ps to stabilize 
potential, kinetic, and total energies as well as to converge temperature to 310 K. NVT 
equilibration was followed by equilibration under NPT ensemble for 800 ps, which was 
to adjust and stabilize the system under constant pressure of 1 bar. During equilibration, 
the backbone atoms of Aβ40 were restrained by imposing 1000 kJ/mol of energy per atom. 
After that, the restraint was released, and the simulations were performed for 150 ns to 
collect the data. The particle-mesh Ewald method was used to deal with the long-distance 
Table 1. Simulation box dimensions Dimensions of 
simulation boxes for the three systems are listed. 
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electrostatic interactions. To control the constant temperature and pressure, Berendsen 
Thermostat and Parrinello-Rahman Barostat were used, respectively. Newton’s equation 
of motion was integrated using Velocity-Verlet algorithm with 2 fs time steps. The 
simulation results were analyzed with built-in functions of GROMACS. 
Methods of Analysis 
Structural Deformation of Aβ40 
 To investigate the structural deformation of Aβ40, we compared structures of the 
three systems at 0, 50, 100, and 150 ns. The images help us visualize how a protein and a 
drug interact with each other throughout the simulation. From the images, we would be 
able to observe whether Aβ40 undergoes conformational changes from α-helices to β-
structures. 
Secondary Structure Analysis using DSSP 
 To investigate the effect of the drugs on the deformation of Aβ40, secondary 
structures of Aβ40 protein in the three systems were analyzed using DSSP [14] 
throughout the simulation time of 150 ns. DSSP classifies the secondary structures by 
specifying the hydrogen bonds based on equations presented by Kabsch and Sanders. 
 DSSP outputs a color map that shows compositions of different secondary 
structures at forty residues of Aβ40 over the entire simulation time, 150 ns. Each color 
represents different kinds of secondary structures such as α-helix to β-structure. 
Root Mean Square Deviation (RMSD)  
Root mean square deviation was used to measure the structural deformation of 
Aβ40 in presence of the drugs over simulation time. RMSD is the averaged fluctuations of 
the atomic positions compared to the reference structures, as shown in equation (2) 
  (2) 
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, where xi, yi, zi represents the x, y, z position at time t and , ,  are initial positions 
of atom i of total number of atoms, N, respectively. RMSD of Aβ40 was estimated from 
the position of the backbone atoms and fitted to the initial structures. Therefore, high 
RMSD indicates significant atomistic displacement throughout MD simulation. This 
means the protein went through conformational changes which require a lot of movement 
of atoms. Numerical results were expressed as mean  ± SD. 
Minimum Distance Calculations 
 Minimum distance between centers of mass of Aβ40 and the drugs was calculated 
to compare binding affinity of ER and EOY as Aβ40 fibrillogenesis inhibitors. The one 
with lower distance values over the simulation time was considered to interact more with 





Structural Deformation of Aβ40 
 At 0 ns, all the systems started with coiled alpha helical structure as shown in 
Table 2. As simulation progressed, the alpha helix of Aβ40 Only gradually deformed into 
β-hairpin structure. On the other hand, when Aβ40 was treated with ER, even though 
some unwinding of alpha helix was observed, the structure was deformed less into the β-
hairpin structure. In contrast to the treatment with ER, when Aβ40 was treated with EOY, 
similar trend to that of ER-treatment was observed up to 50 ns, but after 100 ns, the 
protein started to deform in a way similar to that of Aβ40 Only. 
 0 ns 50 ns 100 ns 150 ns 
Aβ40 Only 
    
Aβ40-ER 
    
Aβ40-EOY 
    
Table 2. Deformation of the Structure of Aβ40 The trajectory images were taken for each 





Figure 3. Secondary structures Using DSSP, secondary structures were 
defined for (A) Aβ40 Only, (B) Aβ40 with ER, and (C) Aβ40 with EOY. 
Secondary Structure Analysis 
 Without any treatment, Aβ40 started to lose its alpha helical structures (blue), 
specifically at residue 15-18 and 35-38 (Figure 3A). Starting from approximately 30 ns, 
β-bridge (black) started to form within those two regions, and by 80 ns β-sheets (red) 
started to form (Figure 3A). When treated with ER, Aβ40 maintained blue regions 
throughout the simulation (Figure 3B), while when treated with EOY, Aβ40 underwent 













     
 13 
 
Root Mean Square Deviation (RMSD) Analysis 
 RMSD of atomistic position was calculated to quantify conformation transition of 
backbone of Aβ40 during the simulations. Without any drug, Aβ40 showed RMSD values 
mostly within the range of 1 – 1.4 nm (Figure 4). RMSD value of this system was 1.152 
nm ± 0.0004 nm. In contrast, when Aβ40 was treated with ER, the overall RMSD values 
were lower than those of Aβ40 Only (Figure 4). Also, maximum value was lower than that 
of Aβ40 Only. RMSD value calculated for ER was 0.86 nm ± 0.002 nm. For EOY 
treatment, RMSD values were higher than those of Aβ40 Only up to about 40 ns (Figure 
4). Later on, the RMSD values were relatively low compared to Aβ40 Only, but overall 
the values were higher than those of ER treatment (Figure 4). The RMSD value for EOY 




Figure 4. Root mean square deviation of Aβ40’s position For the three different systems, 
RMSD of the protein’s displacement was calculated throughout the simulations, and the three 




Figure 5. Distance between the Drug Molecules and Aβ40 Minimum distance 
between the centers of mass of Aβ40 and the two drug molecules – ER and EOY – were 
calculated over the simulation time and plotted with MS Excel. Blue line represents 
distance between ER and Aβ40, and the red represents distance between EOY and the 
protein. 
Minimum Distance Calculations 
 According to Figure 5, despite some fluctuations, the distance between Aβ40 and 
ER stayed approximately 1 nm most of the time. Similar to ER, EOY also showed 
fluctuations in the distance, but it drastically increased to over 2 nm at around 30 ns. 
Then it stayed at values significantly higher than those of ER and tended to even increase 

















Structural Deformation of Aβ40 
 Trajectory images taken at various time points showed how Aβ40 underwent 
conformational change (Table 2). As expected, when no drug molecule was added to 
Aβ40, it started to actively unfold its α-helical structure which is indicated by spring-like 
structure at 0 ns. As time passed, the coiled form became almost not observable, but 
instead, it began to fold into a hairpin-like loop which is a type of β structure. However, 
when treated with ER, the protein did not deform as much as Aβ40 Only did. By 150 ns, 
the α-helical structure was almost maintained. This indicates that ER had effect on 
inhibiting conformational change of Aβ40. On the other hand, effect of EOY was 
questionable. In comparison to Aβ40 Only, EOY seemed to show some effect in the 
beginning of the simulation, but at 100 ns, shape of Aβ40 became similar to that of Aβ40 
Only, which means EOY was not effective anymore from that point. Therefore, it is 
concluded that ER may be an effective drug candidate while EOY is not. 
Secondary Structure Analysis of Aβ40 
 To go deeper into observing secondary structure compositions of Aβ40, DSSP was 
used. The DSSP color maps (Figure 3) show different types of secondary structures at 
forty residues of Aβ40 throughout the simulations. In Figure 3A, continuous black and red 
lines are observable at residue 15-18 and 35-38 from 30 ns, indicating that those residues 
played role in forming β structures. This result agreed with that of the trajectory image 
observation. For the case of ER treatment, however, the continuation of black and red 
lines is not observable but rather blue and yellow blocks. This implies that α-helical and 
coil structures were maintained throughout the simulation, which was also supported by 
the trajectories in Table 2. When Aβ40 was treated with EOY, α-helical structures were 
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disappeared even earlier than Aβ40 Only. Furthermore, EOY-treated Aβ40 began to form 
β-sheet structures at residue 1-5 and 20-23 from 100 ns. Like the result of the trajectory 
image comparison, DSSP analysis result displayed much poorer effect of EOY than ER. 
Statistical Analysis for Aβ40 Conformational Change 
 Among the three systems, Aβ40 Only showed the most consistently high RMSD 
trend (Figure 4), which indicates that Aβ40 was actively going through conformational 
change from α-helix to β-sheet, as shown in trajectories (Table 2). The mean RMSD 
value of 1.152 was also the highest among the three, and very low SD numerically 
displayed the consistency. However, ER-treated Aβ40 showed fluctuations and sudden 
drops in RMSD values (Figure 4). Furthermore, the mean RMSD value (0.86) was lower 
than that of Aβ40 Only. This means ER played a role in preventing movement of the Aβ40 
backbone, which highly possibly led to inhibition of β-sheet structure formation. In the 
case of EOY, first 40 ns of simulation showed similar trend as the graph for Aβ40 Only. 
But, from 60 ns, EOY seemed to reduce the displacement of Aβ40 backbone shown by 
relatively low RMSD values compared to Aβ40 Only. The amount of reduction was not 
greater than that of ER, but this result was somewhat contradictory to DSSP result for 
EOY which showed that EOY allowed active conformational change of Aβ40 from 100 ns 
(Figure 3). Numerically, the mean RMSD value of EOY was lower than that of Aβ40 
Only but higher than that of ER. Thus, the inhibitory effect of ER was clearly shown 
through RMSD calculation, but the effect of EOY was doubtable. 
Distance between Drugs and Aβ40 
 Distances between the centers of mass of the two compounds and Aβ40 were 
calculated to get insights into their interactions during the simulations. Distance between 
ER and the protein was maintained at relatively low value, which indicated that the two 
molecules were closely and stably bound to each other (Figure 5). This strong and stable 
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binding may have affected ER to effectively perform its function of preventing the 
conformational change of Aβ40. On the other hand, distance between Aβ40 and EOY was 
much higher than the case of ER. The plot of EOY, overall, displayed more fluctuations 
than that of ER, and EOY and Aβ40 were separated even further by the end of the 
simulation (Figure 5). This trend showed that binding interactions between EOY and 
Aβ40 were unstable, thus having possibly contributed to the relative ineffectiveness of 




 Overall, our study has shown that ER is effective, but EOY is rather ineffective in 
terms of reducing the harm of Aβ40 monomer by inhibiting its conformational change. 
Molecular dynamics simulations were run to draw this conclusion. The only structural 
difference between the two compounds is the type of halogen attached to the xanthene 
group which refers to the three connected rings; ER has iodine, and EOY has bromine 
(Figure 1). It is still unsure how the different halogens generate the different outcomes. 
Our simulation result, however, disagrees with the result of our collaborators, Kwon, et 
al., who conducted in vitro studies on ER and its analogs [2]. According to their study, 
among five drug candidates, ER and EOY were the best fibrilliogenesis inhibitors. 
Possibly, the difference in the results might have been due to human error or 
environmental factors in the in vitro study or insufficient accuracy in force field 
development for our simulation. Nevertheless, our study confirmed that halogenation has 
influence on modulating Aβ40’s conformational transition and aggregation. Even though 
more studies are required to understand how different types of halogens contribute to 
fibrillogenesis inhibition differently, small halogenated compounds might be potential Aβ 
modulators. To get an insight into what makes EOY a relatively ineffective inhibitor, 
more different analysis methods will be utilized in the future. In addition to that, in order 
to clearly see the effect of halogenation, we will run more simulations using FLN which 
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